We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Premature Birth Predicted by Immunoassay

By LabMedica International staff writers
Posted on 03 Oct 2012
A blood test has been developed that can predict the likelihood that women with intact membranes with threatened preterm labor will deliver spontaneously within seven days of sampling.

The test is based on testing maternal serum for specific proteins, using multiplex sandwich immunoassay based on flowmetric multiplex technology, which has been used to analyze multiple inflammatory markers and neurotrophins in maternal serum in women with threatened preterm labor (PTL). More...


From 1996 to 2005, an international team working at the Sahlgrenska University Hospital (Gothenburg, Sweden) enrolled 142 healthy women without major medical problems. The women were with singleton pregnancies presenting with threatened PTL between 22 weeks plus 0-7 days and 33 weeks plus 6-7 days of gestation. The assays were based on a newly developed blood test that looks at specific proteins in the woman's blood combined with an already established examination that uses ultrasound to measure the length of the cervix.

Only proteins with detectable maternal serum levels in more than 50% of the samples were included in the analyses. Therefore, interleukins (IL) such as IL-1b, IL-2, IL-5, IL-6, and IL-8 were excluded from further analyses. The statistically highest significant values were detected for IL-10, matrix metalloproteinasis-9 (MMP-9) and migration inhibitory factor (MIF). In the prediction model, levels of maternal serum IL-10 were significantly higher in women who delivered preterm within seven days of sampling, compared with women who delivered later. The study also showed that found that levels of maternal serum chemokine (C-C motif) ligand 5 (RANTES) were statistically higher in women who delivered compared with women who delivered later.

Panagiotis Tsiartas, MD, PhDc, the senior author of the study said, "To have time to give the woman cortisone, which speeds up the development of the fetal lungs, it is common practice to delay the delivery by a couple of days with the help of tocolytic treatment or anti-contraction medications. Being able to predict if a woman who comes to the hospital with preterm contractions will actually give birth early and thereby requires follow-up and possible treatment is therefore very important. Statistically, the method can predict with 75% to 80% accuracy if a woman will give birth early." The study was published September 2012 issue of the British Journal of Obstetrics and Gynaecology.

Related Links:

Sahlgrenska University Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.